Method for interrupting conduction paths within the heart
Summary by NHIP
Transmural Heart Lesion Method
The method creates arrhythmias by forming transmural lesions in atrial walls using opposing internal and external electrodes. Energy transfers from an RF source to an electrode limited to 50 to 70 degrees C while a salt solution contacts the tissue.
Claim Score by NHIP
Abstract
A method for making transmural lesions in one or more walls of the atria of the heart in open-heart surgery. The lesion blocks electrical impulses in a direction crosswise to the lesion. The method uses a probe having a handle (1), a closed electrode (2) at an end of the probe, a relatively rigid member (5) of physiologically acceptable plastic connecting the probe and the electrode, and means (6, 7) for coupling the probe to an RF power source.

Term
Term ended
Expired 9 October 2023, 3 years ago.
- Priority
- Filed
- Granted
- Expired
- Today
29 claims: 2 independent, 27 dependent
- 1Broadest claimClaim Score 52, average(NHIP)A method of creating an arrhythmia in the heart of a patient by ablative treatment of the atrium of the heart comprising:(a) providing a surgical instrument having a handle and a first electrode affixed to the handle;(b) providing a second electrode;(c) providing a power source in electrical connection with the first and second electrodes;(d) performing an open-heart surgical procedure in which a first electrode is placed proximal to a first portion of a wall of the atrium and the second electrode is placed proximal to a second portion of the wall of the atrium such that one of the first and second electrodes is on the inside of the atrium and the other of the first and second electrodes is on the outside of the atrium;(e) transferring energy from the power source to the first electrode to cause a transmural lesion to form in the wall of the atrium between the first and second electrodes.
- 16A method of treating an arrythmia in the heart of a patient by ablative treatment of the atrium of the heart comprising:(a) providing a surgical instrument having a handle with a first electrode affixed to the handle and a fluid outlet;(b) providing a second electrode;(c) providing a power source in electrical connection with the first and second electrodes;(d) performing an open-heart surgical procedure in which the first electrode is placed proximal to a first portion of a wall of the atrium and the second electrode is placed proximal to a second portion of the wall of the atrium such that one of the first and second electrodes is on the inside of the atrium and the other of the first and second electrodes is on the outside of the atrium;(e) transferring a physiologically acceptable liquid to the fluid outlet;(f) transferring energy from the power source to the first electrode to cause a transmural lesion to form in the wall of the atrium between the first and second electrodes.
Independent claims2
34 paragraphs in 6 sections, as filed
CROSS-REFERENCE TO RELATED APPLICATIONS
0001This is a continuation of application Ser. No. 10/277,144, filed Oct. 21, 2002 (now abandoned), which is a continuation of application Ser. No. 09/583,303, filed May 30, 2000 (now U.S. Pat. No. 6,502,575), which is a divisional of application Ser. No. 09/180,124 filed Nov. 2, 1998 (now U.S. Pat. No. 6,165,174), which is the U.S. national phase of PCT application No. PCT/NL97/00223 filed Apr. 25, 1997, which claims priority from Netherlands application No. 1003021, filed May 3, 1996.
FIELD OF THE INVENTION
0002The invention relates to an instrument for making at least one transmural lesion in one or more walls of the atria of the heart, which lesion essentially blocks the electrical impulse conduction in a direction crosswise to the transmural lesion.
BACKGROUND OF THE INVENTION
0003All kinds of heart arrhythmias, and in particular chronic and paroxysmal atrial fibrillation, can currently be treated by surgery.
0004A known surgical procedure (MAZE) was designed to eliminate atrial fibrillation permanently. In this procedure incisions are made with a scalpel in the walls of the atria, in order to block electrical impulse conduction in a direction crosswise to the incisions, by the interruption of the tissue continuity. As a result of the subsequent scarring, these electrical blocks acquire a permanent character.
0005This known technique is as yet performed only to a limited extent worldwide, owing to the complexity of the operation. The increased risk is particularly associated with the duration of the operation and the way in which the operation has to be carried out.
0006The duration of the operation, and in particular the cross-clamp time (x-clamp) is so long that there is a great risk of damage to the heart muscle.
0007The cross-clamp time required for the MAZE procedure alone is currently still an average of 68 min. (range 50–102 min.), and the necessary time on the heart-lung machine is on average 182 min. (range 130–256 min.). For further data you are referred to Atrial Fibrillations: Mechanisms and Therapeutic Strategies, Futura Publishing Co. Inc. Armonk, N.Y. 1994. J. L. Cox: Surgical Interruption of Atrial Reentry as a Cure for Atrial Fibrillation. The way in which the operation is performed with the scalpel produces an increased risk of vascular suture leaks and subsequent bleeding, due to the large number and location of the vascular sutures involved.
SUMMARY OF THE INVENTION
0008The object of the present invention is to provide an instrument of the abovementioned type which eliminates the abovementioned disadvantages, and which in particular shortens the time required for the operation and reduces the risk of bleeding and damage, therefore reducing the risk for the patient in open-heart surgery.
0009According to the invention, the instrument indicated is characterized in that the instrument is a probe in which the end which during the operation comes into contact with the wall to be treated is a closed electrode which can interact with an RF power source, while the probe is of a relatively rigid type.
0010The instrument according to the invention is a probe by means of which in open-heart surgery it is possible to make a permanent change in an atrial wall which is transmural, i.e. it extends over the entire thickness of the wall.
0011As will be discussed at a later stage, during the performance of the operation the electrode at the end of the probe is brought into contact with the atrial wall to be treated and is moved along it in a linear pattern. On excitation of the electrode with RF power, dielectric (RF) heating of the wall tissue occurs. The RF treatment produces a change in the cell structure of the atrial wall, with the result that electrical impulse conduction in a direction crosswise to the transmural lesion is blocked.
0012In order to be able to work well with it, the probe must be of a relatively rigid type, so that the electrode can be accurately positioned on and moved along the atrial wall. In the operation no disintegration of the tissue of the atrial wall occurs, and there is no risk of subsequent bleeding. The operation can be carried out on the outside or the inside of the atrium as desired.
0013Methods of RF heating or dielectric heating are based on the use of heat generated in materials which are relatively poor electrical conductors when they are placed in high-frequency electromagnetic fields. The heat is generated as a result of dielectric losses occurring in a material situated between metal electrodes which form a capacitor which is connected to a high-frequency (RF) generator. Such heating is highly uniform and therefore extremely suitable for use of the instrument, the probe, according to the invention. During use of the probe, one of the capacitor “plates” is formed by the electrode at the end of the probe, while the other “plate” is a counter-electrode which is stuck on, for example, the patient's back; when the latter electrode is being placed, it is preferable to use a contact gel which has electrical conductance. Of course, the counter-electrode can also be placed on the outside of the atrial wall of the heart, for example if the electrode of the probe is being brought into contact with the inside of said wall.
0014In connection with the invention, reference is made to WO 95/03742, which discloses a catheter comprising at the distal a metal electrode by means of which tissue erosion, also known as ablation, can be carried out.
0015Such a catheter typically has a length of approximately 1 meter, a diameter of approximately 2 mm, and has an electrode of approximately 2 mm diameter, and its low thickness makes it very flexible, so that it can follow a blood vessel without any problems. This catheter is suitable for local punctate ablation. Such a catheter is not suitable for use as a probe for making stripe-shaped transmural lesions in an atrial wall.
0016In particular, the probe according to the invention has at least a handle; an end; a relatively rigid member, such as a shaft, between the handle and the end, and connecting and conduction means for connecting the end of the probe to an RF power source.
0017In the instrument according to the invention a temperature recorder is advantageously present near the end of the probe, which temperature recorder, operating in a feedback system with the RF power source, can regulate the temperature of the end of the probe to a preset value. Through input of the RF power, the temperature of the end of the probe will generally rise; feedback with the RF power source makes it possible to ensure that the temperature of the end does not exceed a predetermined value.
0018With use of RF power it is extremely important that the fewest possible electrical blockages should be present in the body section between the end of the probe and the counter-electrode on the outside of the body. On account of this, it is preferable to ensure that the probe can interact with means for supplying a physiologically acceptable liquid to the end thereof. In its simplest form, such a liquid is supplied near the electrode of the probe by way of a line which does not form part of the probe. The function of the liquid is, on the one hand, to cool the electrode and, on the other, to prevent the occurrence of electrically insulating air gaps which adversely affect the efficiency of the RF action.
0019It is very advantageous for the probe according to the invention itself to have means for discharging a physiologically acceptable liquid near the end of the probe. Said liquid will generally preferably have a certain degree of electrical conduction, and is expediently a physiological salt solution.
0020In a very attractive embodiment, the instrument has between the handle of the probe and the shaft inlet means for introducing the physiologically acceptable liquid, which inside the shaft remains electrically insulated from the connecting and conduction means present in the shaft, while near the end it has outflow means for the physiologically acceptable liquid. With this embodiment, the functioning of the probe can be improved yet further, and it can be ensured that the greatest RF energy effect is concentrated in the wall of the atrium to be treated, forming the desired transmural lesion.
0021At the side of the handle facing away from the end of the probe, the conduction and connecting means of the probe according to the invention comprise a connector connected thereto, with contact means for connection of the electrode to the end of the probe and the temperature recorder present therein to the RF power source.
0022The connector is preferably of the rapid coupling type, so that easy coupling to the RF power source is permitted.
0023In order to make handling of the instrument according to the invention, in the form of a probe, as easy as possible for the operating surgeon during an open-heart operation, the shaft of the probe preferably has an intrinsic curvature, which is expediently approximately 140 degrees.
BRIEF DESCRIPTION OF THE DRAWINGS
0024The invention will now be explained with reference to the drawing, in which:
0025<figref idref="DRAWINGS">FIG. 1</figref> shows a schematic picture of the transmural lesions which can be made with the instrument according to the invention, and which can block electrical impulses in directions crosswise to said lesions;
0026<figref idref="DRAWINGS">FIG. 2</figref> shows an instrument according to the invention in a first embodiment;
0027<figref idref="DRAWINGS">FIG. 3</figref> shows an instrument according to the invention in a second embodiment.
DETAILED DESCRIPTION OF THE DRAWINGS
0028<figref idref="DRAWINGS">FIG. 1</figref> shows diagrammatically in a two-dimensional view the two atria of a human heart, in which the transmural lesions are indicated by reference letter C, the undisturbed electrical impulses by A, and the blocked electrical impulses by B. The lesions C are in the nature of scar tissue which is formed after treatment using the probe according to the invention. The atria, as viewed epicardially, include the left atrium <b>100</b> and the right atrium <b>101</b>. Structural features of the atria include the pulmonary veins <b>110</b>, the inferior vena cava <b>120</b>, the superior vena cava <b>130</b>, the left atrial appendage <b>140</b> and the right atrial appendage <b>150</b>. A first lesion <b>160</b> is a curved lesion that is joined end-to-end such that it encircles the pulmonary veins <b>110</b>, and is between the pulmonary veins <b>110</b> and conductive pathways in the left atrium <b>100</b> and between the pulmonary veins <b>110</b> and conductive pathways in the right atrium <b>101</b>. A second lesion <b>165</b> extends between the superior vena cava <b>130</b> and the inferior vena cava <b>120</b> and blocks a first conductive pathway <b>167</b>. A third lesion <b>170</b> extends across the left atrium <b>100</b> from an intersection <b>171</b> with a portion of the first lesion <b>160</b> toward the left atrial appendage <b>140</b> and blocks a second conductive pathway <b>172</b>. A fourth lesion <b>175</b> extends along the right atrium <b>101</b> laterally from an intersection <b>176</b> with a portion of the second lesion <b>165</b>. A fifth lesion <b>180</b> extends from a portion of the first lesion <b>160</b> along the left atrium <b>100</b> and blocks a third conductive pathway <b>182</b>. A sixth lesion <b>185</b> extends along the right atrium <b>101</b> toward the right atrial appendage <b>150</b>.
0029<figref idref="DRAWINGS">FIG. 2</figref> shows a probe according to the invention in a first embodiment, and shows a handle <b>1</b>, an active metal end <b>2</b> as a closed electrode with indication of the position of a temperature sensor <b>3</b>. The shaft of the probe <b>5</b> has a curvature <b>4</b> of approximately 140 degrees, and inside the shaft run the electrical wires <b>6</b> for exciting the closed electrode-type end <b>2</b> and wire <b>7</b> for connecting the temperature sensor which is fitted at the position of reference number <b>3</b>.
0030Inside the handle <b>1</b> are electrical switch means <b>10</b> (not shown in any further detail) for permitting connection of the probe to the RF generator (not shown). Reference numbers <b>8</b> and <b>9</b> also indicate a connector making it possible to couple the probe to the RF <b>5</b> generator.
0031<figref idref="DRAWINGS">FIG. 3</figref> shows a particularly advantageous embodiment of the probe according to the invention, which is identical to the probe of <figref idref="DRAWINGS">FIG. 2</figref>, but in which reference number <b>11</b> indicates a Y-connector which makes it possible to supply a physiologically acceptable liquid by way of a port <b>12</b> into the shaft <b>5</b>, said physiologically acceptable liquid being guided through the shaft <b>5</b> without contact with the conduction means <b>6</b> and <b>7</b>. The physiologically acceptable solution flows by way of the port <b>12</b> to an inner shaft <b>13</b>, and from there by way of the shaft <b>5</b> to the outflow ports <b>14</b> which are disposed in the vicinity of the metal end <b>2</b>. The physiologically acceptable liquid is expediently a physiological salt solution which is readily tolerated by the body.
0032The physiological salt solution, on the one hand, achieves cooling of the closed electrode <b>2</b> and, on the other hand, lowers the electrical resistance between the closed electrode of the end <b>2</b> and the atrial wall. Extremely good and reproducible results are obtained with the probe shown in the figure. The source of RF power is typically a generator which can deliver a power of, for example, maximum 50 watt at a frequency of 500 kHz. The power supplied is a function of the temperature set and the tissue contact of the electrode forming the end of the probe. The desired temperature can be set at the generator, and in general lies in the range 50 to 70 degrees C. If temperatures higher than the given range are permitted, burning of the tissue (coagulation) will occur, with the result that an insulating layer is formed; said layer will make further action of the RF energy difficult, with the result that underlying tissue is not treated fully, if at all.
0033The end <b>2</b> of the probe expediently comprises platinum and is typically a cylindrical shape with a diameter of 4 mm. The diameter can generally lie between 3 and 6 mm.
0034The total length of the probe without connection means is typically approximately 35 cm, the handle being approximately 20 cm long, the shaft approximately 10 cm, and the end approximately 2 cm. In general, the length of the shaft <b>5</b> lies between 8 and 15 cm, and the shaft has a diameter between 3 and 6 mm and is made of a physiologically acceptable plastic. Suitable plastics are nylon <b>66</b>, polypropylene and high-density polyethylene.
Contents6
4 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| US9216055B2 | Cited by | United States of America | Applicant |
| US9713495B2 | Cited by | United States of America | Applicant |
| US9504523B2 | Cited by | United States of America | Applicant |
| US3736936A | Cites | United States of America | Applicant |
| US3807403A | Cites | United States of America | Applicant |
| US3823575A | Cites | United States of America | Applicant |
| US3823718A | Cites | United States of America | Applicant |
| US3827436A | Cites | United States of America | Applicant |
| US3830239A | Cites | United States of America | Applicant |
| US3859986A | Cites | United States of America | Applicant |
| US3862627A | Cites | United States of America | Applicant |
| US3886945A | Cites | United States of America | Applicant |
| US3907339A | Cites | United States of America | Applicant |
| US3910277A | Cites | United States of America | Applicant |
| US3913581A | Cites | United States of America | Applicant |
| US3924628A | Cites | United States of America | Applicant |
| US4018227A | Cites | United States of America | Applicant |
| US4022215A | Cites | United States of America | Applicant |
| US4061135A | Cites | United States of America | Applicant |
| US4063560A | Cites | United States of America | Applicant |
| US4072152A | Cites | United States of America | Applicant |
| US4082096A | Cites | United States of America | Applicant |
| US4207897A | Cites | United States of America | Applicant |
| US4248224A | Cites | United States of America | Applicant |
| US4275734A | Cites | United States of America | Applicant |
| US4278090A | Cites | United States of America | Applicant |
| US4377168A | Cites | United States of America | Applicant |
| US4519389A | Cites | United States of America | Applicant |
| US4562838A | Cites | United States of America | Applicant |
| US4598698A | Cites | United States of America | Applicant |
| US4601290A | Cites | United States of America | Applicant |
| US4664110A | Cites | United States of America | Applicant |
| US4736749A | Cites | United States of America | Applicant |
| US4779611A | Cites | United States of America | Applicant |
| US4802475A | Cites | United States of America | Applicant |
| US4815470A | Cites | United States of America | Applicant |
| US4872346A | Cites | United States of America | Applicant |
| US4916922A | Cites | United States of America | Applicant |
| US4917095A | Cites | United States of America | Applicant |
| US4920978A | Cites | United States of America | Applicant |
| US4936281A | Cites | United States of America | Applicant |
| US4946460A | Cites | United States of America | Applicant |
| US5013312A | Cites | United States of America | Applicant |
| US5029574A | Cites | United States of America | Applicant |
| US5044165A | Cites | United States of America | Applicant |
| US5078713A | Cites | United States of America | Applicant |
| US5080102A | Cites | United States of America | Applicant |
| US5080660A | Cites | United States of America | Applicant |
| US5100388A | Cites | United States of America | Applicant |
| US5108390A | Cites | United States of America | Applicant |
| US5147355A | Cites | United States of America | Applicant |
| US5167659A | Cites | United States of America | Applicant |
| US5178133A | Cites | United States of America | Applicant |
| US5207674A | Cites | United States of America | Applicant |
| US5217860A | Cites | United States of America | Applicant |
| US5222501A | Cites | United States of America | Applicant |
| US5224943A | Cites | United States of America | Applicant |
| US5228923A | Cites | United States of America | Applicant |
| US5231995A | Cites | United States of America | Applicant |
| US5232516A | Cites | United States of America | Applicant |
| US5246440A | Cites | United States of America | Applicant |
| US5254116A | Cites | United States of America | Applicant |
| US5263493A | Cites | United States of America | Applicant |
| US5269291A | Cites | United States of America | Applicant |
| US5275595A | Cites | United States of America | Applicant |
| US5277201A | Cites | United States of America | Applicant |
| US5277696A | Cites | United States of America | Applicant |
| US5281213A | Cites | United States of America | Applicant |
| US5281215A | Cites | United States of America | Applicant |
| US5295484A | Cites | United States of America | Applicant |
| US5309896A | Cites | United States of America | Applicant |
| US5316000A | Cites | United States of America | Applicant |
| US5317878A | Cites | United States of America | Applicant |
| US5318525A | Cites | United States of America | Applicant |
| US5322520A | Cites | United States of America | Applicant |
| US5323781A | Cites | United States of America | Applicant |
| US5324255A | Cites | United States of America | Applicant |
| US5324284A | Cites | United States of America | Applicant |
| US5324286A | Cites | United States of America | Applicant |
| US5334181A | Cites | United States of America | Applicant |
| US5334193A | Cites | United States of America | Applicant |
| US5348554A | Cites | United States of America | Applicant |
| US5353783A | Cites | United States of America | Applicant |
| US5354258A | Cites | United States of America | Applicant |
| US5361752A | Cites | United States of America | Applicant |
| US5385148A | Cites | United States of America | Applicant |
| US5396887A | Cites | United States of America | Applicant |
| US5397304A | Cites | United States of America | Applicant |
| US5400770A | Cites | United States of America | Applicant |
| US5400783A | Cites | United States of America | Applicant |
| US5403309A | Cites | United States of America | Applicant |
| US5403311A | Cites | United States of America | Applicant |
| US5405376A | Cites | United States of America | Applicant |
| US5409483A | Cites | United States of America | Applicant |
| US5423807A | Cites | United States of America | Applicant |
| US5423811A | Cites | United States of America | Applicant |
| US5427119A | Cites | United States of America | Applicant |
| US5431649A | Cites | United States of America | Applicant |
| US5433708A | Cites | United States of America | Applicant |
| US5435308A | Cites | United States of America | Applicant |
13 members in 6 offices
Priority claims23
| Document | Office | Kind | Date |
|---|---|---|---|
| 1003024 | Netherlands (Kingdom of the) | A | |
| 1003024 | Netherlands (Kingdom of the) | A | |
| 1003024 | Netherlands (Kingdom of the) | – | |
| 9700223 | Netherlands (Kingdom of the) | W | |
| 9700223 | Netherlands (Kingdom of the) | W | |
| 18012498 | United States of America | A | |
| 18012498 | United States of America | A | |
| 58330300 | United States of America | A | |
| 58330300 | United States of America | A | |
| 27714402 | United States of America | A | |
| 27714402 | United States of America | A | |
| 40539203 | United States of America | A | |
| 09180124 | – | – | – |
| 09583303 | – | – | – |
| 1003024 | – | – | – |
| 10277144 | – | – | – |
| NL19961003024 | – | – | – |
| PCTNL9700223 | – | – | – |
| US19980180124 | – | – | – |
| US20000583303 | – | – | – |
| US20020277144 | – | – | – |
| US20030405392 | – | – | – |
| WO1997NL00223 | – | – | – |
Members13
| Document | Office | Kind | |
|---|---|---|---|
| NL1003024C2 | Netherlands (Kingdom of the) | C2 | |
| WO9741793A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU2410097A | Australia | A | |
| EP0918490A2 | European Patent Office (EPO) | A2 | |
| US6165174A | United States of America | A | |
| EP0918490B1 | European Patent Office (EPO) | B1 | |
| DE69704363D1 | Germany | D1 | |
| DE69704363T2 | Germany | T2 | |
| US6502575B1 | United States of America | B1 | |
| US2003045872A1 | United States of America | A1 | |
| US2003191462A1 | United States of America | A1 | |
| US2006084967A1 | United States of America | A1 | |
| US7128740B2This record | United States of America | B2 |
43 transactions on the USPTO file
Allowed after 1 non-final rejection and 1 RCE.
- Non-final rejections
- 1
- Final rejections
- 0
- RCEs
- 1
- Appeals
- 0
Over time
Point at a mark for the transactionTransactions
| Event | Code | |
|---|---|---|
| Payment of Maintenance Fee, 12th Year, Large EntityM1553 | M1553 | |
| Post Issue Communication - Certificate of CorrectionN423 | N423 | |
| Recordation of Patent Grant MailedPGM/ | PGM/ | |
| Patent Issue Date Used in PTA CalculationAllowedPTAC | PTAC | |
| Issue Notification MailedAllowedWPIR | WPIR | |
| Dispatch to FDCD1935 | D1935 | |
| Application Is Considered Ready for IssuePILS | PILS | |
| Issue Fee Payment VerifiedN084 | N084 | |
| Issue Fee Payment ReceivedIFEE | IFEE | |
| Mail Notice of AllowanceAllowedMN/=. | MN/=. | |
| Notice of Allowance Data Verification CompletedAllowedN/=. | N/=. | |
| Date Forwarded to ExaminerFWDX | FWDX | |
| Disposal for a RCE / CPA / R129AbandonedABN9 | ABN9 | |
| Information Disclosure Statement consideredIDSC | IDSC | |
| Reference capture on IDSRCAP | RCAP | |
| Information Disclosure Statement (IDS) FiledM844 | M844 | |
| Information Disclosure Statement (IDS) FiledWIDS | WIDS | |
| Request for Continued Examination (RCE)RCEX | RCEX | |
| Workflow - Request for RCE - BeginBRCE | BRCE | |
| Mail Notice of AllowanceAllowedMN/=. | MN/=. | |
| Mail Examiner's AmendmentMEX.A | MEX.A | |
| Notice of Allowance Data Verification CompletedAllowedN/=. | N/=. | |
| Examiner's Amendment CommunicationEX.A | EX.A | |
| Date Forwarded to ExaminerFWDX | FWDX | |
| Response after Non-Final ActionA... | A... | |
| Request for Extension of Time - GrantedXT/G | XT/G | |
| Mail Non-Final RejectionNon-final rejectionMCTNF | MCTNF | |
| Non-Final RejectionNon-final rejectionCTNF | CTNF | |
| Reference capture on IDSRCAP | RCAP | |
| Information Disclosure Statement (IDS) FiledM844 | M844 | |
| Information Disclosure Statement (IDS) FiledWIDS | WIDS | |
| IFW TSS Processing by Tech Center CompleteTSSCOMP | TSSCOMP | |
| Reference capture on IDSRCAP | RCAP | |
| Case Docketed to Examiner in GAUDOCK | DOCK | |
| Application Return from OIPEWROIPE | WROIPE | |
| Application Is Now CompleteCOMP | COMP | |
| Application Return TO OIPEROIPE | ROIPE | |
| Application Dispatched from OIPEOIPE | OIPE | |
| Application Is Now CompleteCOMP | COMP | |
| IFW Scan & PACR Auto Security ReviewSCAN | SCAN | |
| Information Disclosure Statement (IDS) FiledM844 | M844 | |
| Information Disclosure Statement (IDS) FiledWIDS | WIDS | |
| Initial Exam Team nnIEXX | IEXX |
5 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| Maintenance fee paymentMAFP | MAFP | |
| Fee paymentFPAY | FPAY | |
| Fee paymentFPAY | FPAY | |
| Certificate of correctionCC | CC | |
| Information on status: patent grantGrantedPATENTED CASESTCF | STCF |
Numbers
- Publication
- 07128740
- Publication, DOCDB
- 7128740
- Publication, EPODOC
- US7128740
- Application
- 10405392
- Application, DOCDB
- 40539203
- Application, EPODOC
- US20030405392
Titles
- English
- Method for interrupting conduction paths within the heart
Patent term adjustment
- A delay
- +282 daysthe office missed an examination deadline
- Applicant delay
- −92 days
- Net adjustment
- 190 days
Classification
- CPC, 3
- A61B18/1402
- A61B2017/00247
- A61B2018/00392
- IPC, 4
- A61B18 18
- A61B17 00
- A61B18 14
- A61B19 00
- USPC, 3
- 606041000
- 128898000
- 607122000